Differential proteomics identifies protein biomarkers that predict local relapse of head and neck squamous cell carcinomas

Clinical Cancer Research

Volumn 15, Issue 24, 2009, Pages 7666-7675

  Schaaij Visser, Tieneke B M ^a,b   Graveland, A Peggy ^c   Gauci, Sharon ^a,b   Braakhuis, Boudewijn J M ^c   Buijze, Marijke ^c   Heck, Albert J R ^a,b   Kuik, Dirk J ^c   Bloemena, Elisabeth ^c   Leemans, C René ^c   Slijper, Monique ^a,b   Brakenhoff, Ruud H ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS PROTEOMICS CENTRE   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CORNULIN; CYTOKERATIN 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DYSPLASIA; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; SQUAMOUS CELL CARCINOMA;

EID: 73349136580     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2134     Document Type: Article

References (52)

1. ParkinDM, Bray F, Ferlay J, Pisani P.Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Lam L, Logan RM, Luke C, Rees GL. Retrospective study of survival and treatment pattern in a cohort of patients with oral and oropharyngeal tongue cancers from 1987 to 2004. Oral Oncol 2007;43:150-8.
3. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994;73:187-90.
4. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 1993;71:452-6.
5. Pateromichelakis S, Farahani M, Phillips E, Partridge M. Molecular analysis of paired tumours: time to start treating the field. Oral Oncol 2005;41:916-26.
6. Rosin MP, Lam WL, Poh C, et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res 2002;62:6447-50.
7. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res 2004;10:3607-13.
8. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, et al. Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J Pathol 2002;161:1051-60.
9. Ha PK, Chang SS, Glazer CA, Califano JA, Sidransky D. Molecular techniques and genetic alterations in head and neck cancer. Oral Oncol 2009;45:335-9.
10. Braakhuis BJ, Leemans CR, Brakenhoff RH. A genetic progression model of oral cancer: current evidence and clinical implications. J Oral Pathol Med 2004;33:317-22.
11. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-92.
12. Poh CF, Zhang L, Anderson DW, et al. Fluorescence visualization detection of field alterations in tumor margins of oral cancer patients. Clin Cancer Res 2006;12:6716-22.
13. Roblyer D, Kurachi C, Stepanek V, et al. Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila Pa) 2009;2:423-31.
14. van Houten VM, Leemans CR, Kummer JA, et al. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res 2004; 10:3614-20.
15. Dikshit RP, Boffetta P, Bouchardy C, et al. Risk factors for the development of second primary tumors among men after laryngeal and hypopharyngeal carcinoma. Cancer 2005;103: 2326-33.
16. Tabor MP, Braakhuis BJ, van der Wal JE, et al. Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. J Pathol 2003;199:354-60.
17. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 1978;46:518-39.
18. Tabor MP, Brakenhoff RH, van Houten VM, et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 2001;7: 1523-32.
19. Van Hal NL, Van Dongen GA, Rood-Knippels EM, Van Der Valk P, Snow GB, Brakenhoff RH. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Int J Cancer 1996;68:520-7.
20. Van Hal NL, Van Dongen GA, Ten Brink CB, Herron JN, Snow GB, Brakenhoff RH. Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope. Cancer Immunol Immunother 1997;45:88-92.
21. Bremmer JF, Braakhuis BJ, Brink A, et al. Comparative evaluation of genetic assays to identify oral pre-cancerous fields. J Oral Pathol Med 2008;37:599-606.
22. Friedman DB, Lilley KS. Optimizing the difference gel electrophoresis (DIGE) technology. Methods Mol Biol 2008;428:93-124.
23. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 2005;382:669-78.
24. Kolkman A, Dirksen EH, Slijper M, Heck AJ. Double standards in quantitative proteomics: direct comparative assessment of difference in gel electrophoresis and metabolic stable isotope labeling. Mol Cell Proteomics 2005;4:255-66.
25. Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 2006;1:2856-60.
26. Boersema PJ, Aye TT, van Veen TA, Heck AJ, Mohammed S. Triplex protein quantification based on stable isotope labeling by peptide dimethylation applied to cell and tissue lysates. Proteomics 2008;8:4624-32.
27. Gouw JW, Tops BB, Mortensen P, Heck AJ, Krijgsveld J. Optimizing identification and quantitation of 15N-labeled proteins in comparative proteomics. Anal Chem 2008;80:7796-803.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
29. Peto RPJ. Asymptotically efficient rank invariate test procedures. J R Stat Soc [A] 1972;135: 185-207.
30. Cox D. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
31. Xie H, Onsongo G, Popko J, et al. Proteomics analysis of cells in whole saliva from oral cancer patients via value-added three-dimensional peptide fractionation and tandem mass spectrometry. Mol Cell Proteomics 2008;7:486-98.
32. Weng LP, Wu CC, Hsu BL, et al. Secretomebased identification of Mac-2 binding protein as a potential oral cancer marker involved in cell growth and motility. J Proteome Res 2008; 7:3765-75.
33. Patel V, Hood BL, Molinolo AA, et al. Proteomic analysis of laser-captured paraffinembedded tissues: a molecular portrait of head and neck cancer progression. Clin Cancer Res 2008;14:1002-14.
34. Koehn J, Krapfenbauer K, Huber S, et al. Potential involvement of MYC- and p53-related pathways in tumorigenesis in human oral squamous cell carcinoma revealed by proteomic analysis. J Proteome Res 2008;7:3818-29.
35. Freed GL, Cazares LH, Fichandler CE, et al. Differential capture of serum proteins for expression profiling and biomarker discovery in preand posttreatment head and neck cancer samples. Laryngoscope 2008;118:61-8.
36. Hu S, Arellano M, Boontheung P, et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 2008;14:6246-52.
37. Roesch-Ely M, Nees M, Karsai S, et al. Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 2007;26: 54-64.
38. Matta A, DeSouza LV, Shukla NK, Gupta SD, Ralhan R, Siu KW. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatographytandem mass spectrometry. J Proteome Res 2008;7:2078-87.
39. Ralhan R, Desouza LV, Matta A, et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 2008;7:1162-73.
40. Dirksen EH, Cloos J, Braakhuis BJ, Brakenhoff RH, Heck AJ, Slijper M. Human lymphoblastoid proteome analysis reveals a role for the inhibitor of acetyltransferases complex in DNA doublestrand break response. Cancer Res 2006;66: 1473-80.
41. Contzler R, Favre B, Huber M, Hohl D. Cornulin, a new member of the "fused gene" family, is expressed during epidermal differentiation. J Invest Dermatol 2005;124:990-7.
42. Imai FL, Uzawa K, Nimura Y, et al. Chromosome 1 open reading frame 10 (C1orf10) gene is frequently down-regulated and inhibits cell proliferation in oral squamous cell carcinoma. Int J Biochem Cell Biol 2005;37:1641-55.
43. Xu Z, Wang MR, Xu X, et al. Novel human esophagus-specific gene c1orf10: cDNA cloning, gene structure, and frequent loss of expression in esophageal cancer. Genomics 2000;69: 322-30.
44. Yagui-Beltran A, Craig AL, Lawrie L, et al. The human oesophageal squamous epithelium exhibits a novel type of heat shock protein response. Eur J Biochem 2001;268:5343-55.
45. Baker H, Patel V, Molinolo AA, et al. Proteomewide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral Oncol 2005;41:183-99.
46. Kainuma K, Katsuno S, Hashimoto S, et al. Differences in the expression of genes between normal tissue and squamous cell carcinomas of head and neck using cancer-related gene cDNA microarray. Acta Otolaryngol 2006;126: 967-74.
47. Ohkura S, Kondoh N, Hada A, et al. Differential expression of the keratin-4, -13, -14, -17 and transglutaminase 3 genes during the development of oral squamous cell carcinoma from leukoplakia. Oral Oncol 2005;41:607-13.
48. Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol 2008;129:705-33.
49. Rugg EL, Leigh IM. The keratins and their disorders. Am J Med Genet C Semin Med Genet 2004;131C:4-11.
50. Mallery SR, Zwick JC, Pei P, et al. Topical application of a bioadhesive black raspberry gel modulates gene expression and reduces cyclooxygenase 2 protein in human premalignant oral lesions. Cancer Res 2008;68:4945-57.
51. Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003;21:4546-52.
52. Shumway BS, Kresty LA, Larsen PE, et al. Effects of a topically applied bioadhesive berry gel on loss of heterozygosity indices in premalignant oral lesions. Clin Cancer Res 2008;14: 2421-30.